Table of contents
June 2022 - Volume 81 - Suppl 1
EULAR 2022 European Congress of Rheumatology, 1-4 June. Copenhagen
- Scientific Abstracts
- Oral Presentations
- Addressing the effect of Placebo, Nocebo and Contextual factors in RMDs
- Bench to Bedside: The complement system in rheumatic diseases
- Breaking the barriers: gut, lung and skin in arthritis pathogenesis
- Does AI really help me diagnosing RMDs?
- Is gender sufficiently studied in RMDs?
- Plenary Abstract Session
- AxSpA drug treatment: new and old drugs
- Clinical aspects in Psoriatic Arthritis
- From risk assesment to societal outcomes
- Infection-related and other orphan rheumatic disorders
- Managing chronic pain in RMDs
- Modern biological treatment in RA
- Adaptive immunity (T cells and B cells) in rheumatic diseases / Innate immunity in rheumatic diseases
- Rheumatoid arthritis - aetiology, pathogenesis and animal models
- Rheumatoid arthritis - prognosis and prediction
- The Yin and Yang of scleroderma and vasculitis
- Microbiome and SpA
- The role of the synovial microenvironment during onset and progression of arthritis
- Exploring the origin of inflammation in spondyloarthritis
- From gene to function: genetic basis of rheumatic diseases
- Pregnancy outcomes in rheumatic diseases
- RA: Clinical aspects and comorbidities - I
- Remission, flares and predictive factors in SLE, Sjogren and anti-phospholipid syndrome
- Spondyloarthritis in practice: imaging, outcome assessment and comorbidities
- The treatment and outcome of scleroderma
- Translational and Clinical Research in Crystal Arthritis
- Vaccination against SARS-CoV-2
- Vessels glowing in the dark
- Active Ageing: new perspectives for RMD patients?
- Modern technology for precision medicine
- Rheumatology in Europe
- Vaccination in rheumatic diseases with lessons from COVID
- sJIA vs AOSD: Two names one disease? What have we learnt so far
- Autoinflammation over the course of a lifetime
- Challenges of fibromyalgia
- Long-COVID
- Strengths and weaknesses of experimental models: Moving from animals to human clinical trials
- Improving outcomes for children with JIA
- New developments in OA
- Novel etiopathogenic aspects in SLE and Sjögren’s sydrome
- Osteoporosis
- Outcome of COVID-19 in Rheumatic Diseases
- Emerging treatment strategies in PsA
- RA treatment: modern strategies and new molecules
- RA: Clinical aspects and comorbidities - II
- Recent novelties in SLE/Sjogren and APS?
- The early bird gets the worm
- Sjogren syndrome: from biopsy to lymphoma
- Crystal arthritis
- Rheumatology across boundaries
- How to review a manuscript
- Interstitial lung disease in RMDs
- New lessons for rheumatology in genomics medicine
- Late breaking abstracts
- Poster Tours
- Challenges in measuring and predicting RMDs
- Challenging cases to make you think
- Chronic pain - Mechanisms, epidemiology, and treatment
- Genomics, functional genomics and genetic basis of inflammatory arthritis
- Immunity in Rheumatic Diseases
- Lung involvement in Rheumatic Diseases
- New therapeutic avenues in psoriatic arthritis
- Pathogenesis of SLE, Sjögren’s and antiphospholipid sydrome
- Rheumatoid arthritis – prognosis, predictors and outcome
- Systemic lupus erythematosus, Sjogren's syndrome and anti-phospholipid syndrome
- Through the looking glass
- Biomarkers in pathogenesis, monitoring and treatment of rheumatic diseases
- Clinical aspect of spondyloarthritis
- Health services research: scoping the landscape
- Improving our care and understanding of paediatric RMDs
- New insights into the associations of outcomes and biomarkers in OA
- New options in SLE-Sjogren and APS
- Outcome of COVID-19 in patients with rheumatic diseases
- RA comorbidities
- Recent advances in orphan rheumatic diseases
- Remodelling in OA
- Rheumatoid arthritis: JAKi and beyond
- Small vessels on fire
- Vaccination against SARS-CoV-2
- Achy-Breaky vessels
- Advances in Crystal Arthritis
- All you want to know about bDMARDs in RA
- AxSpA: About treatments and outcomes
- Clinical aspects in Psoriatic Arthritis
- Mortality, Co-morbidity and disease burden
- New data on pathophysiology of spondyloarthritis including psoriatic arthritis
- New insights into the management of JIA
- Novel molecular regulators of bone turnover
- Systemic Lupus Erythematosus: monitoring and management
- Telemedicine what does it tell us
- What’s new in scleroderma and myositis?
- POSTERS only
- Genomics, genetic basis of disease and functional genomics
- Adaptive immunity (T cells and B cells) in rheumatic diseases
- Innate immunity in rheumatic diseases
- Osteo arthritis, aetiology, pathology and animal models
- Rheumatoid arthritis - aetiology, pathogenesis and animal models
- Spondyloarthritis - aetiology, pathogenesis and animal models
- SLE, Sjögren’s and APS - aetiology, pathogenesis and animal models
- Systemic sclerosis, myositis and related syndromes - aetiology, pathogenesis and animal models
- Vasculitis - aetiology, pathogenesis and animal models
- Basic and translational science in paediatric rheumatology
- Basic and translational pain science
- Rheumatoid arthritis - prognosis, predictors and outcome
- Rheumatoid arthritis - comorbidity and clinical aspects
- Rheumatoid arthritis - biological DMARDs
- Rheumatoid arthritis - non biologic treatment and small molecules
- SLE, Sjögren’s and APS – treatment
- SLE, Sjögren’s and APS - clinical aspects (other than treatment)
- Vasculitis – large vessel vasculitis
- Vasculitis – small vessel vasculitis
- Scleroderma, myositis and related syndromes
- Spondyloarthritis – treatment
- Spondyloarthritis - clinical aspects (other than treatment)
- Psoriatic arthritis – treatment
- Psoriatic arthritis - clinical aspects (other than treatment)
- Osteoarthritis
- Osteoporosis
- Crystal diseases, metabolic bone diseases other than osteoporosis
- Infection-related rheumatic diseases
- COVID-19
- Pain in rheumatic diseases, including fibromyalgia
- Spine, mechanical musculoskeletal problems, local soft tissue disorders
- Paediatric rheumatology
- Other orphan diseases
- Diagnostics and imaging procedures
- Public health, health services research, and health economics
- Epidemiology, risk factors for disease or disease progression
- Validation of outcome measures and biomarkers
- Rehabilitation
- Education
- Educational cases
- Publication Only
- Genomics, genetic basis of disease and functional genomics
- Adaptive immunity (T cells and B cells) in rheumatic diseases
- Innate immunity in rheumatic diseases
- Osteo arthritis, aetiology, pathology and animal models
- Bone diseases, aetiology, pathology and animal models
- Rheumatoid arthritis - aetiology, pathogenesis and animal models
- Spondyloarthritis - aetiology, pathogenesis and animal models
- SLE, Sjögren’s and APS - aetiology, pathogenesis and animal models
- Systemic sclerosis, myositis and related syndromes - aetiology, pathogenesis and animal models
- Vasculitis - aetiology, pathogenesis and animal models
- Basic and translational science in paediatric rheumatology
- Basic and translational pain science
- Rheumatoid arthritis - prognosis, predictors and outcome
- Rheumatoid arthritis - comorbidity and clinical aspects
- Rheumatoid arthritis - biological DMARDs
- Rheumatoid arthritis - non biologic treatment and small molecules
- SLE, Sjögren’s and APS – treatment
- SLE, Sjögren’s and APS - clinical aspects (other than treatment)
- Vasculitis – large vessel vasculitis
- Vasculitis – small vessel vasculitis
- Scleroderma, myositis and related syndromes
- Spondyloarthritis – treatment
- Spondyloarthritis - clinical aspects (other than treatment)
- Psoriatic arthritis – treatment
- Psoriatic arthritis - clinical aspects (other than treatment)
- Osteoarthritis
- Osteoporosis
- Crystal diseases, metabolic bone diseases other than osteoporosis
- Infection-related rheumatic diseases
- COVID-19
- Pain in rheumatic diseases, including fibromyalgia
- Spine, mechanical musculoskeletal problems, local soft tissue disorders
- Paediatric rheumatology
- Other orphan diseases
- Diagnostics and imaging procedures
- Public health, health services research, and health economics
- Epidemiology, risk factors for disease or disease progression
- Validation of outcome measures and biomarkers
- Rehabilitation
- Education
- Educational cases
- Oral Presentations
- Health Professionals in Rheumatology Abstracts
- Oral Presentations
- "Not another pill!" Integrative pain management approaches
- HPR: From prevention to management
- How do we overcome the research-to-practice gap? Implementation of evidence into the rheumatology practice
- HPR interventions on the spotlight
- Lifestyle and Disease activity in inflammatory arthritis
- Complexity of care in RMD: intersection between health and social care
- Facilitating work participation – why and how?
- Digital-Health and Tailored Interventions for Improving Patients’ Adherence: Opportunities and Challenges
- Keeping the "Dark clouds" away: Psychological distress and RMDs
- Poster Tours
- POSTERS only
- HPR Measuring health (development and measurement properties of PROs, tests, devices)
- HPR Epidemiology and public health (including prevention)
- HPR Interventions (educational, physical, social and psychological)
- HPR Patients’ perspectives, functioning and health (descriptive: qualitative or quantitative)
- HPR Service developments, innovation and economics in healthcare
- HPR Professional education, training and competencies
- HPR Interdisciplinary research
- Publication Only
- HPR Measuring health (development and measurement properties of PROs, tests, devices)
- HPR Epidemiology and public health (including prevention)
- HPR Interventions (educational, physical, social and psychological)
- HPR Patients’ perspectives, functioning and health (descriptive: qualitative or quantitative)
- HPR Service developments, innovation and economics in healthcare
- HPR Professional education, training and competencies
- HPR Interdisciplinary research
- Oral Presentations
- People with Arthritis and Rheumatism in Europe Abstracts
- Oral Presentations
- How to maintain your quality of life after an RMD diagnosis
- In dialogue with the expert: axSpA and Sjögren’s syndrome
- From childhood to adulthood - growing up with an RMD
- From abstract to concrete – the variety of activities of PARE organizations
- Enhancing research through patient involvement
- The COVID-19 pandemic – what did we learn?
- Volunteering for the RMD Community
- Poster Tours
- POSTERS only
- Publication Only
- Oral Presentations